FOR IMMEDIATE RELEASE


            BIO-BRIDGE SCIENCE (BGES.OB) SIGNS EXCLUSIVE DISTRIBUTION
                   AGREEMENT WITH XINHUA SURGICAL INSTRUMENTS

OAK BROOK, ILLINOIS, November 21, 2005 - Bio-Bridge Science, Inc. (OTCBB: BGES)
today announced that it has entered into an exclusive distribution agreement
with Xinhua Surgical Instruments Co., Ltd., located in Shandong, China.

Under the agreement, Bio-Bridge Science has been granted exclusive distribution
rights for all Xinhua surgical instruments in the United States, which are
subject to FDA approval.

Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science said, "We believe that
our agreement with Xinhua will enable us to create a revenue stream as we
develop our vaccine program. We are pleased to be able to offer Xinhua surgical
instruments to potential U.S. customers. Xinhua surgical instruments are
manufactured with German technology and expertise, giving them competitive
advantages in product surface, corrosion resistance, performance, as well as
price. We believe our knowledge of the Chinese and American medical market
should allow us to be effective in introducing the products in the United
States."

About the Company
Bio-Bridge Science, Inc. is a biotechnology firm focused on the development of
vaccines with broad therapeutic and preventive applications. Through its wholly
owned subsidiary in Beijing, Bio-Bridge is developing a HIV Vaccine, that is
expected to enter clinical trials early next year in China. The vaccine, based
on exclusive technology co-developed by CEO Liang Qiao, an associate professor
at Loyola University Chicago's Stritch School of Medicine, is designed to target
infection in mucosal tissues, the first type of tissue attacked by HIV.

About Xinhua
Xinhua Surgical Instruments Co. Ltd. is a world leader in surgical instrument
production that is based in Shandong, China

Forward Looking Statements
This press release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to uncertainties
and risks including, but not limited to, product and service demand and
acceptance, changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks defined in this
document and in statements filed from time to time with the Securities and
Exchange Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. In addition, the company disclaims any
obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to SEC filings for additional
information and accompanying notes to financial statements.

Contact:
Bio-Bridge Science Contact                  Investor Relations:
Dr. Liang Qiao, Chairman & CEO              Leslie Wolf-Creutzfeldt
Tel: 630-928-0869                           Adam Friedman Associates
bbs@bio-bridge-science.com                  212-981-2529x11
                                            leslie@adam-friedman.com